A Foundational Study On Stroke Is Ready. Here Is Why It’s Important
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin a Phase 1 clinical trial in 2022’s fourth quarter.
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Biotech clinical-stage company Algernon Pharmaceuticals Inc.
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Algernon Pharmaceuticals Inc (OTC:AGNPF) has announced topline data showing that it has met the co-primary endpoint in its Phase 2 proof…
There Are Now 50 Psychedelics Companies Listed In The U.S. – Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.